Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, excluding ventilator-associated pneumonia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor targeting cell signaling pathways. The company was founded in 2000 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone41-61-606-1111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$103.15 million
Profitability
Miscellaneous
Employees227
Next Earnings DateN/A
OptionableNot Optionable
Basilea Pharmaceutica (OTCMKTS:BPMUF) Frequently Asked Questions
What is Basilea Pharmaceutica's stock symbol?
Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."
What is the consensus analysts' recommendation for Basilea Pharmaceutica?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Basilea Pharmaceutica.
Has Basilea Pharmaceutica been receiving favorable news coverage?
Headlines about BPMUF stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Basilea Pharmaceutica earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Basilea Pharmaceutica.
Who are some of Basilea Pharmaceutica's key competitors?
Some companies that are related to Basilea Pharmaceutica include Cambrex (CBM), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS), Akcea Therapeutics (AKCA), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT) and Alder Biopharmaceuticals (ALDR).
What other stocks do shareholders of Basilea Pharmaceutica own?
Who are Basilea Pharmaceutica's key executives?
Basilea Pharmaceutica's management team includes the folowing people:
- Mr. David Veitch, Chief Exec. Officer (Age 54)
- Mr. Adesh Kaul, Chief Financial Officer (Age 45)
- Dr. Laurenz Kellenberger, Chief Scientific Officer (Age 52)
- Dr. Marc Engelhardt, Chief Medical Officer (Age 55)
- Dr. Gerrit Hauck, Chief Technology Officer (Age 55)
How do I buy shares of Basilea Pharmaceutica?
Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Basilea Pharmaceutica's stock price today?
One share of BPMUF stock can currently be purchased for approximately $42.28.
How big of a company is Basilea Pharmaceutica?
What is Basilea Pharmaceutica's official website?
How can I contact Basilea Pharmaceutica?
Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at 41-61-606-1111 or via email at [email protected]
MarketBeat Community Rating for Basilea Pharmaceutica (OTCMKTS BPMUF)
| Community Ranking: | | 2.3 out of 5 ( ) |
| Outperform Votes: | | 20 (Thanks for Voting!) |
| Underperform Votes: | | 23 (Thanks for Voting!) |
| Total Votes: | | 43 |
